Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Denmark / NCT04772625
Active, not recruiting Observational

Failure Analysis of Patellofemoral Arthroplasty

NCT04772625 · tracked via the Priya Life Science Denmark tracker
Sponsor
Anders Odgaard
Phase
Observational
Started
2019-01-01
Last updated
2025-07-30

Condition(s) studied

Patellofemoral OsteoarthritisArthroplasty ComplicationsKnee Osteoarthritis

Investigational drug(s) / intervention(s)

Patellofemoral arthroplasty

Patellofemoral arthroplasty: Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.

Study summary

The purpose of the retrospective cohort study is 1) to determine preoperative risk factors for revision af patellofemoral arthroplasty, and 2) to provide a detailed description of indications for revision after patellofemoral arthroplasty. All patients operated with patellofemoral arthroplasty in Denmark from January 1, 2008 to December 31, 2015, will be included in the cohort.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patellofemoral arthroplasty * Primary procedure performed between Jan 1 2008 and Dec 31 2015 * Primary procedure performed in Denmark Exclusion Criteria: * Patella-nail syndrome * Dislocating tendon following patellectomy.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rigshospitalet Copenhagen Denmark

Other trials for the same condition

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis Active, not recruiting
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals Active, not recruiting
Observational Clinical Investigation of Arthrosamid in Knee Osteoarthritis Active, not recruiting
Allogenic Mesenchymal Stem Cell Intraarticular Injection for Knee Osteoarthritis Therapy Recruiting
Anatomic Congruent Prosthetic Knee Design Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04772625 on ClinicalTrials.gov ↗ ← All trials in Denmark